Think of Sulfonylureas as CV Neutral

December 2019

New evidence will provide more reassurance about the cardiovascular safety of sulfonylureas (glimepiride, etc) for type 2 diabetes.

There's been debate for years over whether sulfonylureas increase CV risk...mainly due to data with the old, first-generation tolbutamide.

To date, all sulfonylurea med labels warn of increased CV mortality.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Pneumonia Use Amoxicillin More Often for Outpatients With Community-Acquired Pneumonia
E-Cigarettes Help Patients Break the E-Cigarette Habit
Immunizations Boost Immunization Rates for Immunocompromised Patients
Cannabinoids Clarify the Buzz About Cannabidiol (CBD) for Arthritis
Gastroenterology Know When to Use Antibiotics for Uncomplicated Diverticulitis
Seizures Be Familiar With How Nayzilam Stacks Up Against Diastat AcuDial
Antimicrobial Stewardship Ramp Up Antimicrobial Stewardship in the Community
Diabetes Meds Think of Sulfonylureas as CV Neutral
Pregnancy Evaluate Blood Pressure Closely During Pregnancy
Contraceptives Be Ready for Questions About the Annovera Vaginal Contraceptive Ring
Pneumonia Limit Broad-Spectrum Empiric Antibiotics for Inpatient CAP Treatment
Dermatology Be Ready to Expedite Treatment for Stevens-Johnson or Other Derm Emergencies
Venous Thromboembolism Don't Jump to Extended-Duration VTE Prophylaxis in MEDICAL Patients